Titan Spine Extends its Reach in Europe with Acquisition of Distributor in Spain

Titan Spine LLC entered a distribution agreement with Spain-based MBA to provide Titan’s line of Endoskeleton titanium implants to spine surgeons in six countries across Europe.

Under the agreement, Titan Spine will provide its spinal interbody fusion devices featuring its proprietary surface technology to MBA for distribution in Spain, Portugal, Andorra, Luxembourg, Belgium and the United Kingdom. MBA is an international medical device marketing-and-distribution organization that specializes in the sale of products used for orthopedic and neurosurgery treatments.

In addition, Titan Spine recently opened an office in Valencia, Spain, to support the growing European adoption of its Endoskeleton devices. The Spain office supports sales, training and marketing initiatives across Europe in conjunction with Titan’s European headquarters located in Laichingen, Germany. In addition, the Spain office operates in a strategic capacity to facilitate distribution efforts and relations within the Spanish and Portuguese markets, which  quickly are adopting the company’s titanium devices featuring its proprietary surface technology, according to Titan officials.

“MBA is one of the leaders in distribution of orthopedic and neurosurgical products throughout Europe and offers us a strategic alliance to penetrate the major markets of Spain, Portugal, Belgium and the U.K., which was a critical objective we hoped to achieve this year,” said Marcus Klarl, Titan’s vice president of sales for Europe. “We took this a step farther as we recognized the anticipated demand for on-the-ground support required for a smooth launch. The opening of our newest office, located in Spain, marks a second, complementary focal point in increasing our presence in select European markets that are actively embracing and driving titanium as the material of choice for interbody fusion devices. Surgeons in the Spanish and Portuguese markets in particular reflect an ideal opportunity for Titan because they recognize the need for devices that combine the advantages of titanium with our proprietary surface technology.”

Kevin Gemas, president of Titan Spine, added: “Titan Spine has experienced significant sales growth over the last few years, with particular uptick over the first half of 2015. By broadly expanding our line of titanium spinal implants to surgeons and patients in six additional countries across Europe, we have a greater opportunity to offer the benefits of our subtractive surface technology for surgeons and patients in Europe. We are seeing growing European demand for surface enhanced interbody fusion devices that do not possess the potential hazards associated with additive/coated implants.”

The full line of Endoskeleton devices features Titan Spine’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels created by a subtractive process. The combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the up-regulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins, and “creating the potential for a faster and more robust fusion,” the company claims.

Mequon, Wis.-based Titan Spine is a surface technology company focused on the design and manufacture of interbody fusion devices for the spine.